Immune system mediated cancer cell targeting

Immune system mediated cancer cell targeting refers to the broad set of mechanisms by which immune cells—including cytotoxic T lymphocytes (CD8+ T cells), natural killer (NK) cells, and other components—recognize and eliminate malignant cells. These processes include antigen presentation, T cell activation, immune cell infiltration into tumor sites, and direct or indirect killing of cancer cells through mechanisms such as apoptosis, granule exocytosis, and cytokine production. Modern therapies, such as immune checkpoint inhibitors and adoptive cell transfer, exploit these natural functions to enhance anti-tumor immunity, but the term itself does not describe a single molecular target or receptor[1][2][3][4][5][7]. Key context: - This term covers numerous discrete immune-related molecules (e.g., PD-1, CTLA-4, CAR-T receptors), but is not itself a molecule. - Immune evasion by cancer cells is a major challenge; therapies must overcome molecular and cellular barriers to immune recognition and killing[2][5][7]. - Immunotherapies harness these principles, but target specific molecules or pathways within the broad immune system-cancer interaction[3][4][6].

Other names

Immune-mediated cancer cell killingImmune surveillance of cancerImmune cell-based tumor targeting